Hep C Pharmaceutical Analysis

Satisfactory Essays
Hep C treatement
Harvoni is a new drug used for treating Hep C that was approved by FDA in October 2014. Harvoni is a combination of sofosbuvir (Sovaldi) and ledipasvir. Harvoni is used to treat Hep C genotype one. The recommended dose of Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg, I tab daily for 12 weeks.The medication can be taken with or without food and patients can follow the usual missed-dose instructions (Gritsenko, Hughes). During a phase III clinical trial Harvoni cured more than 97 percent after 12 weeks of treatment. Some patients who have not taken antiviral drugs before were cured in eight weeks of treatemnt (Gritsenko, Hughes). Harvoni has less side effects are compared to other hep c drugs. The most common adverse events reported
Get Access